Melnick David A. Insider Trades

Insider Trading History

Track insider trading activity for Melnick David A.. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Spero Therapeutics
Spero Therapeutics SPRO
Chief Medical Officer
Holding Value $174k 62,081 shares
Last Trade
Feb 01, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$595k 53,190 shares
$11.18
$2.80
Spero Therapeutics
Spero Therapeutics SPRO
Chief Medical Officer
Holding Value $67.4k 24,067 shares
Last Trade
Aug 26, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$400k 24,067 shares
$16.62
$2.80
Spero Therapeutics
Spero Therapeutics SPRO
Chief Medical Officer
Holding Value $161k 57,432 shares
Last Trade
Feb 01, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.1M 57,432 shares
$19.18
$2.80
Spero Therapeutics
Spero Therapeutics SPRO
Chief Medical Officer
Holding Value $154k 55,000 shares
Last Trade
Feb 03, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$514k 55,000 shares
$9.34
$2.80
Spero Therapeutics
Spero Therapeutics SPRO
Chief Medical Officer
Holding Value $182k 65,000 shares
Last Trade
Jan 02, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$407k 65,000 shares
$6.26
$2.80
Spero Therapeutics
Spero Therapeutics SPRO
Chief Medical Officer
Holding Value $378k 135,000 shares
Last Trade
Jan 04, 2018 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.64M 135,000 shares
$12.14
$2.80

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up